ACADIA Pharmaceuticals Inc. (ACAD) Stake Maintained by Winslow Evans & Crocker Inc.

Winslow Evans & Crocker Inc. maintained its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 5,100 shares of the biopharmaceutical company’s stock at the end of the second quarter. Winslow Evans & Crocker Inc.’s holdings in ACADIA Pharmaceuticals were worth $142,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. increased its position in ACADIA Pharmaceuticals by 4.9% in the first quarter. Vanguard Group Inc. now owns 7,469,785 shares of the biopharmaceutical company’s stock valued at $256,812,000 after buying an additional 348,141 shares during the last quarter. BlackRock Inc. increased its position in ACADIA Pharmaceuticals by 5,422.8% in the first quarter. BlackRock Inc. now owns 5,433,209 shares of the biopharmaceutical company’s stock valued at $186,791,000 after buying an additional 5,334,832 shares during the last quarter. OppenheimerFunds Inc. increased its position in ACADIA Pharmaceuticals by 3.6% in the first quarter. OppenheimerFunds Inc. now owns 4,918,286 shares of the biopharmaceutical company’s stock valued at $169,090,000 after buying an additional 170,289 shares during the last quarter. Janus Capital Management LLC increased its position in ACADIA Pharmaceuticals by 0.8% in the first quarter. Janus Capital Management LLC now owns 3,418,861 shares of the biopharmaceutical company’s stock valued at $117,539,000 after buying an additional 26,690 shares during the last quarter. Finally, Point72 Asset Management L.P. increased its position in ACADIA Pharmaceuticals by 57.6% in the first quarter. Point72 Asset Management L.P. now owns 1,931,200 shares of the biopharmaceutical company’s stock valued at $66,395,000 after buying an additional 706,200 shares during the last quarter. 97.34% of the stock is currently owned by institutional investors.

Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) traded up 3.24% on Friday, hitting $31.21. The stock had a trading volume of 2,092,205 shares. The company’s market capitalization is $3.82 billion. ACADIA Pharmaceuticals Inc. has a 1-year low of $20.68 and a 1-year high of $40.83. The firm has a 50-day moving average of $29.35 and a 200 day moving average of $32.02.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.17. ACADIA Pharmaceuticals had a negative net margin of 485.14% and a negative return on equity of 62.08%. The company had revenue of $30.50 million during the quarter, compared to the consensus estimate of $20.02 million. During the same period in the previous year, the firm posted ($0.63) EPS. The firm’s revenue was up 30400.0% compared to the same quarter last year. On average, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post ($2.58) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “ACADIA Pharmaceuticals Inc. (ACAD) Stake Maintained by Winslow Evans & Crocker Inc.” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this story on another publication, it was illegally stolen and reposted in violation of international copyright and trademark law. The correct version of this story can be viewed at https://www.baseball-news-blog.com/2017/08/13/winslow-evans-crocker-inc-maintains-stake-in-acadia-pharmaceuticals-inc-acad-updated-updated-updated.html.

Several equities research analysts recently issued reports on ACAD shares. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research note on Wednesday, May 10th. Zacks Investment Research upgraded ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating and set a $31.00 price target for the company in a research note on Tuesday, July 11th. BidaskClub upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, June 21st. Rodman & Renshaw reiterated a “buy” rating and issued a $60.00 price target on shares of ACADIA Pharmaceuticals in a research note on Monday, May 22nd. Finally, ValuEngine upgraded ACADIA Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, June 2nd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus target price of $43.23.

In other ACADIA Pharmaceuticals news, EVP Glenn Baity sold 38,097 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $30.00, for a total value of $1,142,910.00. Following the completion of the sale, the executive vice president now directly owns 109,253 shares of the company’s stock, valued at $3,277,590. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 54,322 shares of company stock valued at $1,699,551 over the last three months. 22.25% of the stock is currently owned by insiders.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for central nervous system (CNS) disorders. Its lead drug candidate, NUPLAZID (pimavanserin), is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PD Psychosis).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply